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Abstract
Background: Lipid oxidation of membrane phospholipids is accompanied by the formation of oxidation-specific
epitopes (OSE). These epitopes are recognized by specific antibodies and represent danger-associated molecular
patterns that are generated during chronic inflammatory processes. In a murine model for hepatic inflammation
during non-alcoholic fatty liver disease (NAFLD), increased antibody levels targeting OSE were found to be protective.
Here, our aim was to determine an association between OSE-specific antibody titers and NAFLD in humans.
Methods: IgM and IgG levels with specificity for various OSE were assessed in the plasma of patients with NAFLD
(n = 71) and healthy controls (n = 68). Antibody titers were comprehensively analyzed in patients with NAFLD
after classification by histological evaluation of liver biopsies. Statistical analysis was performed to determine
significant correlations and odds ratios. To study the specificity for NAFLD, plasma antibody titers were measured
in patients with hepatitis C (n = 40) and inflammatory bowel disease (n = 62).
Results: IgM titers against OSE were lower in patients with NAFLD compared to controls. Further biopsy-based
classification of patients with NAFLD did not show any difference in IgM levels. Plasma IgM titers towards the P1
mimotope demonstrated an inverse correlation with markers for obesity, systemic inflammation, and liver
damage. In contrast, hepatitis C and increased disease activity during inflammatory bowel disease was not
associated with reduced IgM titers.
Conclusions: Our data highlight the importance of immune recognition of OSE by IgM antibodies in the
pathophysiology of NAFLD.
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Background
Non-alcoholic fatty liver disease (NAFLD) constitutes a
spectrum of liver diseases characterized by hepatic lipid
accumulation (steatosis), which when combined with
hepatic inflammation is known as non-alcoholic steato-
hepatitis (NASH). Steatosis is generally considered to be
a benign and reversible condition that is present in
about two thirds of patients with the metabolic syn-
drome [1]. The presence of inflammation in a fatty liver
is thought to drive disease progression, including the de-
velopment of fibrosis, cirrhosis, or hepatocellular carcin-
oma, ultimately requiring liver transplantation [2]. The
mechanisms leading to hepatic inflammation are cur-
rently not fully understood. Hence, therapy options are
limited and accurate, early, non-invasive diagnostic tools
are lacking [3].
Immune reactions triggered by oxidative stress have
been shown to be involved during the progression of
NAFLD to fibrosis [4]. Moreover, oxidized low-density
lipoproteins (OxLDL) are known to play a major role in
atherosclerosis and various other related metabolic dis-
turbances, such as NASH [5]. The oxidation of LDL is
accompanied by the formation of various epitopes on
the surface of OxLDL, called oxidation-specific epi-
topes (OSE) [6]. These epitopes include protein ad-
ducts with lipid peroxidation breakdown products,
such as malondialdehyde (MDA), malondialdehyde-
acetaldehyde (MAA), and 4-hydroxynonenal, as well as
with phosphocholine (PC)-containing oxidized phos-
pholipids [6]. OSE on the surface of OxLDL are recog-
nized by both innate and acquired humoral immunity,
including specific antibodies that are found in the
plasma of humans and animal models [6, 7]. Evidence
for a protective role of OSE-specific immunoglobulin
M (IgM) antibodies in NASH is based on our findings
that increased IgM levels protect from hepatic inflam-
mation in hyperlipidemic mice [8]. To summarize, immu-
nized Ldlr−/− mice with heat-inactivated pneumococci,
which induce the production of anti-OxLDL IgM due to
molecular mimicry with OxLDL, had less hepatic inflam-
mation than control mice after a Western diet. Moreover,
we recently showed that increased levels of IgM antibodies
as a result of Siglec-G deficiency inhibits diet-induced
hepatic inflammation and atherosclerosis in Ldlr−/− mice
[9]. However, the relationship between plasma antibody
levels targeting OSE and hepatic inflammation during
NAFLD has not been investigated in humans so far.
Here, we aimed to determine an association between
plasma antibodies targeting OSE and NAFLD in humans.
For this purpose, IgM and IgG antibody titers against dif-
ferent model epitopes of oxidized lipids were measured in
the plasma of patients with NAFLD and compared to
those in control subjects. Liver biopsies from patients with
biopsy-proven NASH were examined for the presence of
MDA epitopes by immunohistochemistry. Additionally, to
test the specificity of our findings for NAFLD, antibody
levels were determined in two cohorts consisting of pa-
tients with hepatitis C and inflammatory bowel disease
(IBD). Our data highlight the importance of immune rec-
ognition of OSE by IgM antibodies in NAFLD and suggest
that low IgM levels against end products of lipid oxidation
during fatty liver disease are a consequence of obesity.
Methods
Antigens and antibodies
Human MDA-LDL, MAA-LDL, CuOx-LDL, and PC-
BSA were prepared as previously described [10]. MDA2
(a kind gift from Dr J. L. Witztum, San Diego, CA, USA)
is a murine IgG monoclonal antibody against MDA-
lysine epitopes. Linear peptide P1 (HSWTNSWMATFL)
was purchased from Peptide 2.0 Inc. (Chantilly, VA, USA).
Immunohistochemistry
Immunohistochemistry for MDA using the monoclonal
antibody MDA2 was performed on 10 liver biopsies di-
agnosed as NASH, originating from the Maastricht Path-
ology Tissue Collection. Collection, storage, and use of
tissue and patient data were performed in agreement
with the “Code for Proper Secondary Use of Human
Tissue in the Netherlands” (http://www.federa.org).
The staining was performed as described previously
(antibody dilution 1:2000) and biopsies were evaluated
for the presence of MDA [10].
Chemiluminescent ELISA
Chemiluminescent ELISA was performed as previously
described [10]. In brief, purified anti-human IgM (BD
Pharmingen, San Jose, CA, USA) and antigens (MDA-
LDL, MAA-LDL, CuOx-LDL, PC-BSA) at concentrations
of 5 μg/ml in 50 μl phosphate-buffered saline (PBS)-EDTA
were added to each well of a 96-well white, round-bottom
microtitration plate (MicrofluorII roundbottom; Thermo,
Rochester, New York, USA) and incubated overnight at 4 °
C. P1 peptide (Peptide 2.0 Inc.) was coated at 10 μg/ml in
NaHCO3 (pH 8.5) coating buffer and incubated overnight
at 4 °C. After washing and blocking with Tris-buffered sa-
line (TBS) with or without EDTA (pH 7.4, containing 1 %
bovine serum albumin (BSA), 30 min at room
temperature), the plate was incubated with plasma sam-
ples in their respective dilutions (total IgM: 1:40,000;
MDA-LDL, MAA-LDL, P-1, Cu-OxLDL, PC-BSA IgM/
IgG: 1:200) in 1 % BSA in TBS with EDTA (pH 7.4) for
2 h at room temperature or overnight at 4 °C. Alkaline
phosphatase (AP)-labeled goat anti-human IgM (μ-chain
specific; Sigma-Aldrich, Vienna, Austria; 1:50,000 in TBS-
BSA) or AP-labeled goat anti-human IgG (γ-chain spe-
cific; Sigma-Aldrich, Vienna, Austria; 1:50,000 in TBS-
BSA) was used for detection. AP-conjugated secondary
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reagents were detected using Lumi-Phos (Lumigen, South-
field, Michigan, USA; 33 % solution in water) and a Syn-
ergy 2 Luminometer (BioTek, Winooski, Vermont, USA).
Washing steps were performed on an ELx405 Select Deep
Well Microplate Washer (BioTek, Winooski, Vermont,
USA) with PBS or PBS-EDTA. Internal controls were
included on each microtiter plate to detect potential varia-
tions between microtiter plates. The intra-assay coeffi-
cients of variation for all assays were 5–15 %.
NAFLD cohort for antibody measurements
Healthy controls (n = 68) were recruited by advertisement
and patients classified as NAFLD (n = 53) were recruited
from the metabolic clinics of the Cleveland Clinic and
MetroHealth Medical Center in Cleveland, OH, USA. The
study protocol was approved by the Institutional Review
Boards at the Cleveland Clinic and MetroHealth Medical
Center. A detailed clinical history was obtained for each
participant, followed by a physical examination. Hepatic
ultrasonography was performed on all participants by the
same investigator (S. Dasarathy) in order to confirm the ab-
sence of steatosis in controls. Moreover, plasma transamin-
ase levels were determined in all participants. Where
steatosis and increased plasma transaminase levels were de-
tected, a liver biopsy was taken for further characterization
of NAFLD. Liver biopsies from patients were reviewed in a
blinded manner by the same pathologist and NASH was
defined as an NAFLD activity score ≥4 and a histologic
diagnosis of NASH by the pathologist. Participants with
other forms of chronic liver disease were excluded by
screening for autoimmune liver disease (autoimmune hepa-
titis, primary biliary cirrhosis, sclerosing cholangitis), for
metabolic liver disease (hemochromatosis, Wilson’s dis-
ease), for alpha-1 antitrypsin deficiency, and for viral hepa-
titis (hepatitis B and hepatitis C). Participants with a history
of daily alcohol intake (women >20 g, men >30 g), intraven-
ous drug use, or a history of bowel surgery were also ex-
cluded. None of the participants were on any medications
known to cause hepatic steatosis or taking vitamin supple-
ments. Written informed consent was obtained from all
participants after having the procedure fully explained.
Blood and liver sampling was done as described before
[11–13]. Plasma samples were used to perform the anti-
body determinations. Relevant clinical data, including gen-
der, age, weight, and height, together with inflammatory
and liver blood test results, were collected at the time of
liver biopsy and are represented in Table 1. The body mass
index (BMI) was calculated using the formula: weight (kg)/
[height (m)]2. Further clinical and biochemical data for all
patients are summarized in Table 1 (Additional file 1).
Hepatitis C cohort
Healthy controls (n = 20) were recruited by advertise-
ment and patients with chronic hepatitis C (n = 20) were
recruited from the Department of Internal Medicine III,
Division of Gastroenterology and Hepatology, Medical
University of Vienna, Austria. The study protocol was
approved by the Institutional Review Boards at the Med-
ical University of Vienna. Hepatic ultrasonography and
liver biopsy was performed on all participants prior to
scheduled antiviral therapy. Moreover, plasma transamin-
ase levels were determined in all participants. Liver biop-
sies of patients were reviewed in a blinded manner by two
independent pathologists. Participants with other forms of
chronic liver disease or with a history of daily alcohol in-
take were excluded by screening. Written informed con-
sent was obtained from all participants after having the
procedure fully explained. Further clinical data for the pa-
tients are summarized in Table 2 (Additional file 2).
Patients with inflammatory bowel disease
Between September 2009 and December 2010, consecutive
patients with IBD were recruited during routine follow-up
at the Gastroenterology Outpatient Clinic of the MUMC+
and participated in a prospective 1-year follow-up study
[14]. All patients had an established diagnosis of IBD based
on clinical, endoscopic, histological, and/or radiological cri-
teria. Demographic and clinical data were obtained using
the MUMC+ computer-based medical registration data-
base. Disease phenotype at the time of diagnosis was deter-
mined by the Montreal classification [15]. The study was
approved by the Medical Ethics Committee of MUMC+
and written informed consent was obtained prior to par-
ticipation. A subset of patients who underwent an endos-
copy for clinical reasons was included for the present
study. Disease activity was assessed during endoscopy by
an experienced gastroenterologist (MP) as inactive (0),
mild (1), moderate (2), or severe (3) (Additional file 3).
Statistical analysis
Continuous variables are presented as means and stand-
ard deviations or as medians and interquartile ranges for
skewed distributions. Categorical data are presented as
absolute frequencies and percentages. Student’s t-test
or the Mann–Whitney U test (for non-normally dis-
tributed data) was used to compare a variable between
two subgroups. Multivariate logistic regression models
were used to assess the association between P1-specific
IgM levels and NAFLD in the specific cohort after
adjusting for age, gender, BMI, and total IgM levels.
All reported p-values are two-tailed and considered
significant at p < 0.05. Statistical procedures were car-
ried out using Graphad Prism 6 or IBM SPSS 20.
Results
MDA epitopes are present in livers of patients with NASH
To determine whether OSE are generated during the
spectrum of NAFLD, immunohistochemical staining for
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MDA epitopes with the monoclonal antibody MDA2
was performed on liver biopsies of patients with biopsy-
proven NASH. As illustrated in Fig. 1a–c, small clusters
of MDA2-positive staining were detected between swol-
len hepatocytes of liver biopsies from patients with
NASH, indicating the presence of MDA epitopes.
IgM antibody titers towards different OSE are lower in
patients with NAFLD
To investigate the potential relationship between anti-
bodies specifically targeting epitopes of OxLDL and
NAFLD, IgM and IgG antibody titers against MDA,
MAA (an immunodominant advanced MDA-lysine ad-
duct), P1 (a highly specific peptide mimotope of MAA
[10]), Cu-OxLDL, and PC-BSA were measured in the
plasma of patients with NAFLD (n = 71) and control
participants with confirmed absence of steatosis (n = 68).
The values of the different measurements were tested
for normality with Shapiro–Wilks test and the results in-
dicated that data were not normally distributed for most
of the measurements in either of the groups (Additional
Table 1 Clinical and biological characteristics of patients with non-alcoholic steatohepatitis for antibody measurements
Participant characteristics (mean ± SD)
Controls
(n = 68)
NAFLD
(simple steatosis)
(n = 18)
NAFLD
(NASH)
(n = 53)
Male/female 27/41 9/9 24/29
Age (y) 40.9 ± 12 45.7 ± 13 45.9 ± 10
BMI (kg/m2) 26.3 ± 4.9 33.6 ± 5.6 34.3 ± 4.7
Waist circumference (cm) 89.4 ± 13.7 108.5 ± 12.9 109.0 ± 14.3
Triglycerides (mg/dL)
Median 75 151 160
Interquartile range 48 66 118.5
Cholesterol (mg/dL) 181.33 ± 32.9 197.8 ± 53.2 196.2 ± 43.5
HDL (mg/dL) 54.8 ± 17.7 41.44 ± 8.0 42.87 ± 8.9
LDL (mg/dL) 105.65 ± 26.9 135.3 ± 47.2 122.9 ± 36.3
Markers of inflammation and liver blood tests (mean (IQR))
TNF-α (pg/ml) 2.5 (0.7) 3 (2.3) 3 (1.9)
MCP-1 (pg/ml) 96.9 (27) 122.4 (24.05) 120.1 (37.95)
IL-1β (pg/ml) 0.42 (0.87) 0.27 (0.36) 0.17 (0.64)
IL-6 (pg/ml) 13.2 (35.8) 16.1 (8.1) 24.5 (45.25)
IL-8 (pg/ml) 5.4 (4) 5.34 (3.5) 7.7 (8.05)
γGT (IU/L) - 51.6 (22.7) 55.6 (32)
Leptin 11.1 (8.8) 23.0 (15.8) 30.5 (18.5)
AST (IU/L) 21 (9) 28 (11.8) 49 (56.5)
ALT (IU/L) 18 (8) 38 (22.8) 66 (99.5)
AST/ALT ratio 1.3 (0.25) 0.8 (0.2) 0.8 (0.4)
AST aspartate transaminase, ALT alanine transaminase, BMI body mass index, γGT gamma-glutamyltransferase, HDL high-density lipoprotein, IL interleukin, IQR
interquartile range, LDL low-density lipoprotein, MCP-1 monocyte chemoattractant protein-1, NAFLD non-alcoholic fatty liver disease, NASH non-alcoholic steatohepatitis,
TNF-α tumor necrosis factor alpha
Table 2 Clinical characteristics of patients with hepatitis C
Participant characteristics (mean ± SD)
Controls
(n = 20)
Hepatitis C
(n = 20)
Male/female 12/8 11/9
Age (y) 48.4 ± 14 48.2 ± 12
Triglycerides (mg/dL) 95.1 ± 52.3 111.25 ± 57.3
Cholesterol (mg/dL) 197.05 ± 31 162.6 ± 40.9
HDL (mg/dL) 71.2 ± 14.5 43.2 ± 16.2
LDL (mg/dL) 106.83 ± 27.1 97.1 ± 38.5
γGT (IU/L) 18.5 ± 6.5 265.1 ± 344.1
AST (IU/L) 24.9 ± 13 113.7 ± 94
ALT (IU/L) 22.7 ± 10.4 127.1 ± 86.3
AST/ALT ratio 1.13 ± 0.27 0.95 ± 0.55
AST aspartate transaminase, ALT alanine transaminase, γGT gamma-
glutamyltransferase, HDL high-density lipoprotein, LDL low-density lipoprotein
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file 4: Table S1). Therefore, all data were logarithmically
transformed (log10) and represented using a log10 scale
in Fig. 1. The observed relative lights units can be found
in Additional file 4: Table S2.
In line with our expectations, patients with NAFLD
had significantly lower IgM titers than controls against
MDA-LDL (4.755 versus 4.819 log10 RLU/100 ms, p =
0.0019; Fig. 1c, Additional file 4: Table S2), MAA-LDL
(4.801 versus 4.868 log10 RLU/100 ms, p = 0.0026;
Fig. 1d, Additional file 4: Table S2), P1 (3.877 versus 4.08
log10 RLU/100 ms, p < 0.0001; Fig. 1e, Additional file 4:
Table S2), CuOx-LDL (4.46 versus 4.612 log10 RLU/
100 ms, p = 0.0004; Fig. 1f, Additional file 4: Table S2),
and PC-BSA (4.255 versus 4.383 log10 RLU/100 ms, p =
0.0096; Fig. 1g, Additional file 4: Table S2). No differ-
ences were found in specific IgG antibody titers towards
the different epitopes of OxLDL in patients with NAFLD
compared to controls (Additional file 4: Table S3).
Interestingly, total IgM antibodies were also significantly
lower in patients with NAFLD compared to healthy par-
ticipants (3.773 versus 3.712 log10 RLU/100 ms, p =
0.0044; Fig. 1h, Additional file 4: Table S2). Notably, IgM
titers towards the specific P1 mimotope, which showed
the strongest reduction in patients with NAFLD com-
pared to controls, remained significant after adjusting for
total IgM levels (0.3074 versus 0.1658 (ratio), p = 0.0002,
Fig. 1i). These data point towards a negative association
between IgM antibodies and oxidized lipids and fatty
liver disease, and indicate an important role for lipid
oxidation in NAFLD.
Plasma anti-P1 IgM levels are reduced in the early phase
of NAFLD and are not influenced by inflammation or
fibrosis
Because anti-P1 IgM levels showed the strongest reduc-
tion in patients with NAFLD and due to its high clinical
Fig. 1 Malondialdehyde (MDA) epitopes in livers of patients with non-alcoholic steatohepatitis (NASH) and relationship between plasma
immunoglobulin M (IgM) titers and non-alcoholic fatty liver disease (NAFLD). Immunohistochemical detection of MDA epitopes in liver sections
(magnification 20×) of a a negative control and b two patients with NASH – arrows indicate localization of MDA2-positive staining in the liver tissue.
Plasma IgM antibody titers against c MDA-low-density lipoprotein (LDL), d malondialdehyde-acetaldehyde (MAA)-LDL, e P1 mimotope, f CuOx-LDL,
g PC-BSA, and h total IgM levels in patients with NAFLD and healthy controls. i Ratio of anti-P1 IgM titers to total IgM levels in patients with NAFLD
and controls. Data are expressed in log10 relative light units (RLU)/100 ms. *p < 0.05, **p < 0.01, ***p < 0.001
Hendrikx et al. BMC Medicine  (2016) 14:107 Page 5 of 13
reproducibility, further analyses were conducted using
the anti-P1 IgM measurements. To determine in which
phase in the disease spectrum of NAFLD that plasma
IgM titers towards P1 are reduced, participants were di-
vided according to their ALT levels (<25, 25–50, >50 IU/
L) because a normal ALT level is expected to be <50 IU/
L. Interestingly, P1-IgM levels were reduced in partici-
pants with moderately elevated ALT levels (25–50 IU/L)
or high ALT levels (>50 IU/L) when compared with the
P1-IgM levels of participants with ALT levels <25 IU/L
(Fig. 2a). Moreover, more than 90 % of control partici-
pants were classified as having low ALT levels. These
data suggest that IgM titers are already lower in early
phases of NAFLD, before liver damage is detected based
on ALT levels.
Next, we evaluated the relationship between IgM to P1
and different classifications based on histological scoring
of liver biopsies taken from patients with NAFLD. First,
the potential of anti-P1 IgM to distinguish simple steatosis
from NASH was tested. Whereas IgM titers were lower in
NAFLD compared with controls, no difference was ob-
served in specific IgM levels between patients with steato-
sis and NASH (Fig. 2b). Moreover, no differences were
observed in plasma P1-IgM titers after classifying the pa-
tients according to a score for steatosis (Fig. 2c), inflam-
mation (Fig. 2d), hepatocyte ballooning (Fig. 2e), the
NAFLD activity score (NAS) (Fig. 2f), or for fibrosis
(Fig. 2g). These data further suggest that antibodies recog-
nizing oxidized lipids are involved during early processes
in the development of NAFLD.
Low IgM titers against the P1 mimotope have a high
predictive value for the presence of NAFLD
To determine the power of low plasma IgM titers
against the P1 mimotope to predict the presence of fatty
liver disease, age, gender, BMI, total IgM levels, and
anti-P1 IgM levels were combined in a single logistic re-
gression model. To account for skewness in their distri-
bution, base-2 logarithms of P1-specific IgM levels were
used in the model. Thus, adjusted odds ratios (OR) for
Fig. 2 Relationship between plasma P1-immunoglobulin (IgM) levels and non-alcoholic fatty liver disease (NAFLD) upon further characterization of
liver biopsies. a IgM titers towards P1 in controls and patients with NAFLD grouped based on their ALT levels. b Plasma IgM antibody titers against the
P1 mimotope in patients with NAFLD in which the liver biopsy was evaluated and scored as simple steatosis versus non-alcoholic steatohepatitis
(NASH). Anti-P1 IgM titers after scoring liver biopsies for c steatosis, d inflammation, e hepatocyte ballooning, f applying the NAFLD activity score (NAS),
and g scoring fibrosis. Data are expressed in relative light units (RLU)/100 ms and presented as means. **p < 0.01
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this variable reflect the change in odds for an increase of
one log2 (the equivalent of a doubling of the value) in
the measure. Without adjustment for other risk factors,
age (OR = 1.206; confidence interval = 1.039–1.4), BMI
(OR = 1.353; confidence interval = 1.228–1.491), total
IgM (OR = 0.619; confidence interval = 0.431–0.888),
and P1-IgM (OR = 0.428; confidence interval = 0.282–
0.65) were all significant predictors for the presence of
NAFLD, and female gender was not (Additional file 4:
Table S4). Importantly, P1-IgM levels (OR = 0.419; con-
fidence interval = 0.216–0.813) were still a significant
predictor for the presence of NAFLD after adjustment
for age, gender, BMI, and total IgM (Fig. 3a, Additional
file 4: Table S5). Moreover, adjusting for waist circum-
ference instead of BMI in our model did not change the
significance for anti-P1 IgM levels (OR = 0.432; confi-
dence interval = 0.261–0.813) in predicting the presence
of NAFLD (Additional file 4: Table S6 and Additional
file 5: Figure S1). In line with our expectations, BMI
(OR = 1.343; confidence interval = 1.211–1.49) and waist
circumference (OR = 1.666; confidence interval = 1.354–
2.049) were still significant predictors for NAFLD after ad-
justment, whereas other variables lost their significance
(Additional file 4: Tables S5 and S6).
A receiver operating characteristic (ROC) curve analysis
was performed to assess the diagnostic value of anti-P1
IgM titers for NAFLD. An area under the curve (AUC) of
0.703 (confidence interval: 0.617–0.790) for the diagnosis
of NAFLD using IgM titers towards P1 was found (Fig. 3b).
In addition, the measurements of IgM against P1 were di-
vided into quartiles and the OR for NAFLD were com-
puted across these quartiles after adjusting for age, gender,
BMI, and total IgM levels (Fig. 3c, Table 3). Our results in-
dicate that participants in quartile 1 (lowest P1-IgM levels)
had an odds ratio of 5.8 (p = 0.01, confidence interval:
1.209–27.818), indicating an increased likelihood of
NAFLD with decreasing P1-IgM levels, independent of
age, gender, BMI, and total IgM levels (Fig. 3d, Table 3).
Taken together, these data indicate that P1-specific IgM ti-
ters have a high predictive value for the presence of
NAFLD, independent of total IgM levels.
Anti-P1 IgM titers are not correlated with lipid levels and
negatively correlate with markers for liver damage and
systemic markers of inflammation
First, the correlation between P1-IgM and plasma lipid
levels in all participants was tested. No correlation was
found between IgM levels towards P1 and plasma tri-
glycerides (Pearson R: −0.11, Fig. 4a), cholesterol
(Pearson R: −0.09, Fig. 4b), or LDL (Pearson R: −0.03,
Fig. 4c), well-known indicators for steatosis and risk
factors for NAFLD. Next, we assessed the potential
Controls
NAFLD
Specificity
S
en
si
tiv
ity
AUC:0,703
a b
dc
Fig. 3 Single logistic regression model, odds ratio determination, and receiver operating characteristic (ROC) curve analysis for P1-specific IgM
levels in non-alcoholic fatty liver disease (NAFLD). a Odds ratios for the predictive power of anti-P1 immunoglobulin (IgM) titers (log2 scale) for
fatty liver disease after adjustment for age, gender, body mass index (BMI), and total IgM. b ROC curve analysis for the diagnosis of NAFLD with
P1-IgM. c IgM titers towards P1 were divided into quartiles (black: controls; red: NAFLD) and d the odds ratios P1-IgM (log2 scale) for NAFLD were
computed across these quartiles after adjusting for age, gender, BMI, and total IgM levels. CI confidence interval
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correlation with markers for obesity: BMI, waist cir-
cumference, and leptin concentration. A strong inverse
correlation was observed between P1-IgM and BMI
(Pearson R: −0.28, p = 0.0009, Fig. 4d), waist circumfer-
ence (Pearson R: −0.22, p = 0.02, Fig. 4e), and leptin
concentration (Pearson R: −0.32, p = 0.0026, Fig. 4f).
These data are in line with a previously reported study
showing elevated serum leptin levels during NAFLD [16].
Moreover, obesity, which is a known risk factor for
NAFLD, has been associated with increased leptin levels
[17]. Additionally, we tested the correlation between P1-
IgM and circulatory markers for liver damage, inflamma-
tion, and adipokines. Interestingly, a strong inverse correl-
ation was found between P1-IgM levels and monocyte
chemoattractant protein-1 (MCP-1; Pearson R: −0.39, p =
0.0006, Fig. 4g), IL-6 (Pearson R: −0.24, p = 0.041, Fig. 4h),
and cathepsin D (Pearson R −0.25, p = 0.0033, Fig. 4I),
which we recently validated as a marker for pediatric
NASH. Moreover, anti-P1-IgM titers were inversely
correlated with alanine aminotransferase (ALT; Pearson
R: −0.17, p = 0.047, Additional file 6: Figure S2A) and
aspartate aminotransferase (AST; Pearson R: −0.18, p =
0.037, Additional file 6: Figure S2B) and a trend was
observed with gamma-glutamyltransferase (γGT; Pear-
son R: −0.11, Additional file 6: Figure S2C). These data
indicate that increased liver damage, assessed by AST
and ALT levels, is associated with reduced levels of
IgM antibody titers towards OSE. No correlation was
found with IL-1β (Pearson R: 0.16, Additional file 6:
Figure S2D) or IL-8 (Pearson R: −0.10, Additional file 6:
Table 3 Odds ratios of P1-specific immunoglobulin M levels for
non-alcoholic fatty liver disease
Odds ratio 95 % confidence interval
Quartile 1 5.8 1.209–27.818
Quartile 2 2.431 0.613–9.647
Quartile 3 1.371 0.357–5.26
Quartile 4 1
Adjusted for age, gender, body mass index, and total immunoglobulin M
Fig. 4 Correlation between plasma P1-immunoglobulin M (IgM) levels and plasma lipids and systemic markers of inflammation. Shown are the
Pearson R correlation between plasma IgM titers towards P1 and a plasma triglycerides (TG), b cholesterol, low-density lipoprotein (LDL), d body
mass index (BMI), e waist circumference, f leptin, and the markers for inflammation g monocyte chemoattractant protein 1 (MCP1), h interleukin 6
(IL-6), and i cathepsin D. RLU relative light unit
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Figure S2E). Taken together, these data suggest that im-
mune recognition of oxidized lipids is affected during
obesity and plays an important role during related dis-
eases, such as the early stages of hepatic inflammation
in NAFLD. These results also suggest an indicative role
of low P1-IgM levels in regard to systemic markers of
inflammation and liver damage.
Low OSE-specific IgM levels are not associated with
hepatitis C or IBD-dependent inflammation
To determine the association between plasma P1-IgM
levels and other chronic inflammatory diseases, a separ-
ate analysis was conducted on two cohorts consisting of
patients with hepatitis C or autoimmune IBD. Total and
OSE-specific IgM and IgG antibody titers were assessed
in both cohorts. Total IgM titers were unchanged be-
tween patients with hepatitis C and controls (167 versus
117 mg/dL, Fig. 5a, Additional file 4: Table S7) whereas
total IgG levels were higher in patients with hepatitis C
than in controls (1506 versus 1091 mg/dL, Additional file
4: Table S7). Importantly, in contrast to our findings in
NAFLD, IgM titers towards P1 were higher in patients
with hepatitis C than in controls (99,785 versus 62,828
RLU/100 ms, p < 0.0001, Fig. 5b, Additional file 4: Table
S7). Adjusting for total IgM antibody levels resulted in no
significant differences between the two groups (686 versus
644 (ratio), Fig. 5c). OSE-specific IgG levels were higher in
patients with hepatitis C than in controls (Additional file
4: Table S8). These data further suggest that low levels of
IgM antibodies targeting oxidized lipids are specific for
obesity-related diseases such as NAFLD.
In the IBD cohort (n = 62; mean male age 49.4 years
and female age 54.8 years), 46 had Crohn’s disease (8
ileal, 17 colonic, and 21 ileocolonic), 15 ulcerative colitis
(1 procolitis, 10 distal, and 4 pancolitis), and one patient
had indeterminate colitis. IBD is characterized by fluctu-
ations in the inflammatory state of the gut [18]. The pa-
tients were classified during endoscopy according to the
activity state of inflammation at the time of blood sam-
pling with a score ranging from 0 to 3, in which 0 means
inactive (n = 23), 1–2 refers to mild to moderate activity
(n = 10), and 3 indicates severely active disease (n = 29).
In contrast to our measurements in patients with
NAFLD, total IgM levels were not influenced by the in-
flammatory activity state in patients with IBD (36,025
versus 37,013 versus 40,280 RLU/100 ms, Fig. 5d). Next,
IgM antibody titers towards the P1 mimotope were de-
termined in these patients, reflecting the IgM titers
against OSE. In contrast to the decreased levels found in
the plasma of patients with NAFLD, slightly higher P1-
specific IgM titers were found in the plasma of patients
classified with high activity IBD (score 3) compared to
patients with inactive disease (score 0) (31,052 versus
21,121 RLU/100 ms, p = 0.0383, Fig. 5e). We could not
detect a difference in P1-specific IgM in patients scored
as 0 and 1–2 (21,121 versus 23,060 RLU/100 ms, Fig. 5e),
nor between patients scored as 1–2 and 3 (23,060 versus
31,052 RLU/100 ms, Fig. 5e), respectively. Additionally,
Fig. 5 Plasma immunoglobulin M (IgM) titers in cohorts consisting of patients with hepatitis C or patients with inflammatory bowel disease (IBD).
a Total, b anti-P1 IgM titers, and c P1/total IgM ratio in healthy controls and patients with hepatitis C. Relationship between the activity score
during IBD and d total IgM, e P1-specific IgM, and f P1/total IgM ratio. Inactive disease was given score 0, mild to moderate disease activity was
given a score of 1–2, and severe activity was given a score of 3. Data are expressed in mg/dl or relative light units (RLU)/100 ms and presented as
means and standard deviations. *p < 0.05, ***p < 0.001
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no difference was observed between the groups after
normalization for total IgM levels (0.628 versus 0.608
versus 0.755 (ratio), Fig. 5f ). These data suggest that de-
creased IgM antibody titers towards MDA-type epitopes
are more specifically associated with lipid-induced in-
flammation, as present in obesity-related diseases like
atherosclerosis and in the spectrum of NAFLD.
Discussion
The multifactorial mechanisms responsible for the wors-
ening of NAFLD are still poorly understood. Although
inflammation is believed to set the stage for further pro-
gression into fibrosis and cirrhosis, relevant insights into
underlying pathways are missing. Hence, therapy options
are only partially effective and accurate, non-invasive
diagnostic tools to detect early signs of fatty liver disease
are lacking. In the present study, we assessed the rela-
tionship between antibodies specific for model epitopes
of oxidized lipids and human NAFLD. Our data indicate
an inverse association between OSE-specific IgM titers
and NAFLD, while no association was observed with
hepatitis C or IBD.
Elevated IgM antibody levels to epitopes of OxLDL
due to immunization strategies have been reported in
mouse models of atherosclerosis with distinct athero-
protective functions [19–22]. It has also been demon-
strated that immunization with autologous MDA-LDL
reduces atherosclerotic lesion formation in rabbits and
mice [23, 24]. MDA epitopes were found to be highly
expressed in atherosclerotic lesions [10] and antibodies
recognizing immunogenic lipid peroxidation end prod-
ucts have also been intensively studied in patients with
cardiovascular disease. IgM titers were found to be in-
versely associated with CVD events and low levels of
OSE-specific IgM were shown to be associated with an
increased risk for myocardial infarction [25, 26]. Also,
during NASH, lipid peroxidation as a result of steatosis
and the consequential formation of OSE such as MDA
have been implicated. In addition, IgM antibodies target-
ing these OSE have been proposed to be protective against
hepatic inflammation [8]. In line with our current data, we
have previously shown that immunization of hyperlipid-
emic Ldlr−/− mice leads to reduced hepatic inflammation
upon high-cholesterol diet due to increased IgM titers to-
wards PC, another OSE [8]. We have recently shown that
deficiency of Siglec-G, a negative regulator of B-cells that
results in increased B-1 cells and OSE-specific IgM anti-
bodies, inhibits diet-induced hepatic inflammation and
atherosclerosis [9]. Taken together, our current findings
further support the idea that IgM targeting OxLDL and/
or specific OSE play an important role during chronic
fatty liver disease.
Immune reactions triggered by oxidative stress have
been shown to be involved during the progression of
NAFLD to fibrosis [4]. In line with data from patients
with alcoholic liver disease [27], increased IgG levels
against antigens derived from lipid peroxidation, such as
proteins adducted with MDA, have been found in pa-
tients with established fibrosis [4]. An explanation for
this association may be the potential dual effect of MDA
adducts on hepatic stellate cells. It was shown that MDA
is specifically recognized by hepatic stellate cells via an
interaction with CD36 scavenger receptors [28], thereby
potentially stimulating the production of collagen and fi-
bronectin, and promoting an immune response towards
MDA as human hepatic stellate cells can promote
lymphocyte proliferation [29]. Another study demon-
strated that serum IgA levels are elevated in patients
with late-stage NASH in comparison with those with
early-stage NASH [30]. More recently, a study by
McPherson et al. indicated that serum IgA levels are fre-
quently elevated in patients with NAFLD and could be
useful to predict advanced fibrosis [31]. These findings
were confirmed in a study by Maleki et al., showing that
IgA levels are useful to evaluate the severity of liver fi-
brosis [32]. In both studies, total IgM levels were deter-
mined in addition to IgA levels. In line with our data, no
differences were observed in the levels of total IgM anti-
bodies in patients with late-stage NASH compared to
patients with early-stage NASH, or between patients
with different stages of fibrosis [30, 31]. Nevertheless,
because IgM antibody titers targeting OSE were not de-
termined in these studies it is not possible to conclude
any association between levels of OSE-specific IgM to
NASH development in these cohorts. Additional investi-
gations of IgM antibodies towards different OSE, and in
particular the P1 mimotope, in multiple larger cohorts
are necessary to confirm the inverse correlation with
NAFLD. It will be particularly interesting to follow up
anti-OSE-IgM levels in patients with NAFLD and NASH
who undergo treatment or lifestyle changes.
Recently, Tsiantoulas et al. showed that MDA epitopes
are present on circulating microparticles and are recog-
nized by specific IgM antibodies, thereby potentially
dampening their pro-inflammatory effects [33]. Micro-
particles are part of a group of extracellular vesicles
(0.1–1 μm in diameter) produced and released by bud-
ding from the plasma membrane upon activation or
apoptosis of different cell types, including monocytes
[34]. Microparticles have been found to play an import-
ant role in NAFLD and related diseases (reviewed in
[35]). Patients with NASH were shown to have increased
numbers of circulating microparticles from invariant nat-
ural killer T cells and macrophages/monocytes (CD14+),
dominant cell types in mediating the pathogenesis of
NASH [36]. Moreover, the level of microparticles, which
was shown to correlate positively with ALT and disease se-
verity, has been proposed as a new biomarker for NASH
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[36]. Another study has recently demonstrated that lipids
induce microparticle release from hepatocytes, which acti-
vate macrophages and lead to an inflammatory response
in NASH [37]. In line with our described findings, one
may hypothesize that increased levels of microparticles
due to lipid overload during the onset of NAFLD and
NASH result in a consumption of OSE-specific IgM. Fur-
ther studies are needed to address the role and interplay
between microparticles and OSE-specific antibodies in the
pathogenesis of fatty liver disease.
The similarities between atherosclerosis and NAFLD,
and our observations regarding the correlations with
BMI and waist circumference allow us to hypothesize
that low IgM titers towards oxidized lipids are a conse-
quence of obesity and are specifically associated with re-
lated diseases. In contrast to lipid-induced inflammation
during obesity, IBD is believed to result from an in-
appropriate inflammatory response to intestinal mi-
crobes in a genetically susceptible host [18]. Altered
serum IgG levels have previously been found in patients
with IBD [38, 39]: serum IgG subclass IgG1 and IgG3
levels were elevated in ulcerative colitis, and IgG2 and
IgG4 levels were increased in patients with Crohn’s dis-
ease. In line with our findings, no significant differences
were found in total IgM concentration, whereas anti-
OSE-IgM titers were not determined [38]. Further, dif-
ferent serum immunoglobulins were recently reported in
patients with IBD in a cross-sectional study [40]. Similar
to our observation, no correlation was found between
disease activity during IBD and IgM levels [40].
Importantly, increased serum levels of MDA and lipid
oxidation were found to be present in individuals with
chronic hepatitis C [41], which might be reflected in a
different host immune response towards epitopes of lipid
oxidation, thereby limiting the specificity for our find-
ings towards NAFLD. In line with previous reported
findings, total and OSE-specific IgG antibodies were in-
creased in patients with hepatitis C compared to healthy
controls [42–45], indicative of an increased immune re-
sponse towards oxidative lipids in hepatitis C. Moreover,
in contrast to our findings in NAFLD, IgM titers to-
wards P1 are increased in patients with hepatitis C com-
pared to controls. However, adjusting for total IgM
antibody levels indicates no differences between the two
groups. Besides our findings in patients with IBD, these
data indicate that reduced levels of IgM antibodies tar-
geting oxidation products of lipids are not specific to fatty
liver disease but rather associated with obesity-related dis-
eases such as atherosclerosis and NAFLD/NASH. Never-
theless, additional validation in other cohorts with
different chronic liver diseases is needed to support the
specificity of low OSE-specific IgM titers in NAFLD.
So far, the reason behind the lower OSE-specific IgM
levels in comparison to healthy participants is not clear.
Similar to the view in CVD [26], one possible explan-
ation is that, during NAFLD, there is increased con-
sumption of IgM antibodies due to increased levels of
OSE and ultimately increased clearance and/or uptake in
the vessel wall. Alternatively, it is possible that genetic
variation leading to lower basal IgM levels are the
underlying cause for patients being at higher risk for de-
veloping lipid-induced related diseases such as athero-
sclerosis and NAFLD/NASH. In the latter case, low
OSE-specific IgM levels should be considered a risk fac-
tor for developing fatty liver disease. Further research is
needed to understand why basal differences in OSE-
specific IgM levels exist and whether this can be seen as
a risk factor for NAFLD.
Conclusions
In the current manuscript we point out that IgM titers
to epitopes on oxidized lipids are negatively associated
with NAFLD using the P1 mimotope, which serves as a
highly reproducible antigen to assess antibody titers in
patients. While the link between anti-P1 IgM measure-
ments and NAFLD, which is independent of classical
risk factors for NAFLD, provides critical insights into
the pathophysiology of chronic fatty liver disease, plasma
levels of anti-P1 IgM are not suitable as a biomarker for
the progression of NAFLD. This conclusion is based on
the inability of anti-P1 IgM titers to distinguish steatosis
from NASH, the correlation between P1 IgM titers to
BMI, and the large overlap between NAFLD and control
participants for the different measurements. Of note, our
findings suggest that obesity/hyperlipidemia is a causal
factor for reduced IgM levels, rendering people more
prone to develop fatty liver disease and related disorders
such as atherosclerosis. Additional studies assessing IgM
antibodies towards different OSE, and in particular the P1
mimotope, in multiple larger cohorts are necessary to
confirm the inverse correlation with NAFLD and to ad-
dress the potential causal link with obesity.
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